GLP-1 Market
LLY $1164.89 ▲ +1.0% NVO $39.80 ▼ -8.0% PFE $27.74 ▲ +0.3% VKTX $30.11 ▲ +3.9% KLRA $11.99 ▼ -6.5% GPCR $36.81 ▲ +5.2% RHHBY $55.30 ▲ +2.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Naltrexone and Bupropion Combination

Company
Yale University
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 22, 2026

Find a Clinical Trial Near Me

See recruiting studies for Naltrexone and Bupropion Combination and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07213466

    Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

    Not yet reported Mayo Clinic 100 participants Est. completion 2029-02-01 1 site
    Other conditions: Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
    View official trial listing →
  • Completed NCT NCT02317744

    Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo

    Not yet reported Yale University 22 participants Est. completion 2016-09 1 site
    Other conditions: Binge Eating Disorder
    View official trial listing →
  • Completed NCT NCT02736474

    Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia

    Not yet reported Shanghai Mental Health Center 22 participants Est. completion 2018-07
    Other conditions: Obese, Cigarette-smoking, Schizophrenia
    View official trial listing →
  • Completed NCT NCT02745912

    Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy Participants

    Not yet reported Orexigen Therapeutics, Inc 30 participants Est. completion 2016-08
    Other conditions: Healthy Subjects
    View official trial listing →
  • Completed NCT NCT05157698

    Pharmacological and Behavioral Treatment After Bariatric Surgery

    Not yet reported Yale University 84 participants Est. completion 2026-05-25 1 site
    Other conditions: Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.